Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Theralase Technologies Inc. (TLT.V)
Toronto, ON, CA
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Theralase Technologies Inc. is based in Toronto, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -6.25% | -29.69% | -21.05% | +45.16% | +36.36% | +18.42% | -6.25% | -10.00% | -39.19% | -43.75% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%-21.0% Q1'26: +45.4% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+7.9% Q1'26: +33.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-490.6% Q1'26: -185.1% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%-499.6% Q1'26: -776.9% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%-198.7% Q1'26: -299.2% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+5.4% Q1'26: +7.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-0.12× Q1'26: -0.11× (vs Q1'25)
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.34M
est: 2.02M (+16.3%)
|
1.73M
est: 2.69M (-35.6%)
|
964.1K
est: 815.0K (+18.3%)
|
929.1K
est: 929.0K (+0.0%)
|
780.6K
est: 867.0K (-10.0%)
|
1.14M
est: 1.14M (0.0%)
|
1.07M
est: 1.07M (+0.0%)
|
1.03M
est: 1.03M (+0.0%)
|
816.5K
est: 880.0K (-7.2%)
|
1.25M
1.25M – 1.25M
+41.9% YoY
|
33.89M
33.89M – 33.89M
+2,613.2% YoY
|
74.69M
74.69M – 74.69M
+120.4% YoY
|
115.46M
115.46M – 115.46M
+54.6% YoY
|
156.35M
156.35M – 156.35M
+35.4% YoY
|
| EBITDA |
-5.83M
est: -2.02M (-189.4%)
|
-3.14M
est: -2.69M (-16.7%)
|
-7.15M
est: -815.0K (-776.8%)
|
-5.56M
est: -929.0K (-498.1%)
|
-4.31M
est: -867.0K (-397.3%)
|
-4.90M
est: -1.14M (-330.3%)
|
-4.25M
est: -1.07M (-297.6%)
|
-3.96M
est: -1.03M (-283.3%)
|
-3.91M
est: -880.0K (-344.3%)
|
-1.25M
-1.25M – -1.25M
-41.9% YoY
|
-33.89M
-33.89M – -33.89M
-2,613.2% YoY
|
-74.69M
-74.69M – -74.69M
-120.4% YoY
|
-115.46M
-115.46M – -115.46M
-54.6% YoY
|
-156.35M
-156.35M – -156.35M
-35.4% YoY
|
| EBIT |
-6.09M
est: -2.02M (-202.4%)
|
-3.36M
est: -2.69M (-24.6%)
|
-7.40M
est: -815.0K (-808.2%)
|
-5.59M
est: -929.0K (-501.6%)
|
-4.41M
est: -867.0K (-408.2%)
|
-5.21M
est: -1.14M (-357.8%)
|
-4.54M
est: -1.07M (-324.3%)
|
-4.23M
est: -1.03M (-309.7%)
|
-4.08M
est: -880.0K (-363.5%)
|
-1.25M
-1.25M – -1.25M
-41.9% YoY
|
-33.89M
-33.89M – -33.89M
-2,613.2% YoY
|
-74.69M
-74.69M – -74.69M
-120.4% YoY
|
-115.46M
-115.46M – -115.46M
-54.6% YoY
|
-156.35M
-156.35M – -156.35M
-35.4% YoY
|
| Net Income |
-6.09M
est: -7.20M (+15.4%)
|
-3.36M
est: -9.60M (+65.0%)
|
-7.43M
est: -9.60M (+22.7%)
|
-5.61M
est: -7.20M (+22.1%)
|
-4.42M
est: -4.80M (+8.0%)
|
-5.25M
est: -7.20M (+27.1%)
|
-4.57M
est: -2.40M (-90.4%)
|
-4.26M
est: -3.29M (-29.3%)
|
-4.12M
est: -2.53M (-62.8%)
|
-2.53M
-2.53M – -2.53M
+0.0% YoY
|
5.06M
5.06M – 5.06M
+300.0% YoY
|
12.66M
12.66M – 12.66M
+150.0% YoY
|
22.78M
22.78M – 22.78M
+80.0% YoY
|
32.91M
32.91M – 32.91M
+44.4% YoY
|
| SGA |
4.78M
est: 4.17M (+14.6%)
|
2.57M
est: 5.57M (-53.9%)
|
3.25M
est: 1.69M (+92.6%)
|
2.47M
est: 1.92M (+28.6%)
|
1.85M
est: 1.79M (+3.1%)
|
1.53M
est: 2.36M (-35.1%)
|
2.13M
est: 2.21M (-3.9%)
|
2.05M
est: 2.13M (-4.0%)
|
2.16M
est: 1.82M (+18.8%)
|
2.58M
2.58M – 2.58M
+41.9% YoY
|
70.00M
70.00M – 70.00M
+2,613.2% YoY
|
154.29M
154.29M – 154.29M
+120.4% YoY
|
238.49M
238.49M – 238.49M
+54.6% YoY
|
322.96M
322.96M – 322.96M
+35.4% YoY
|
| EPS |
-0.05
est: -0.03 (-63.7%)
|
-0.03
est: -0.04 (+35.8%)
|
-0.05
est: -0.04 (-28.3%)
|
-0.03
est: -0.03 (+8.3%)
|
-0.02
est: -0.02 (-8.0%)
|
-0.03
est: -0.03 (+16.0%)
|
-0.02
est: -0.01 (-108.0%)
|
-0.02
est: -0.01 (-36.2%)
|
-0.02
est: -0.01 (-63.0%)
|
-0.01
-0.01 – -0.01
+0.0% YoY
|
0.02
0.02 – 0.02
+300.0% YoY
|
0.05
0.05 – 0.05
+150.0% YoY
|
0.09
0.09 – 0.09
+80.0% YoY
|
0.13
0.13 – 0.13
+44.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Roger John Dumoulin-White | President, Chief Executive Officer & Director | 410.0K | male |
| Arkady Mandel DSc. | Chief Scientific Officer & Director | 310.0K | — |
| Kristina Hachey | Chief Financial Officer & Director | 260.0K | female |
| David Groves | President of World Trade Division | — | male |
| Terry Ruch | Equine Medical Consultant | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TLT.V
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
